LYNK PHARMACEUTICALS
LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.
LYNK PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2018-01-01
Address:
Hangzhou, Zhejiang, China
Country:
China
Website Url:
http://www.en.lynkpharma.com
Total Employee:
11+
Status:
Active
Contact:
+86 0571-8771117
Email Addresses:
[email protected]
Total Funding:
80 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Domain Not Resolving DigiCert SSL GeoTrust SSL Alibaba HiChina DNS Tengine
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Laekna Therapeutics
Laekna Therapeutics is a biotech company focusing on drug discovery and development.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Employees Featured
Founder
Investors List
Med-Fine Capital
Med-Fine Capital investment in Series B - LYNK Pharmaceuticals
HEDA Ventures
HEDA Ventures investment in Series B - LYNK Pharmaceuticals
Lilly Asia Ventures
Lilly Asia Ventures investment in Series B - LYNK Pharmaceuticals
Legend Capital
Legend Capital investment in Series B - LYNK Pharmaceuticals
New Alliance Capital
New Alliance Capital investment in Series B - LYNK Pharmaceuticals
Legend Capital
Legend Capital investment in Series A - LYNK Pharmaceuticals
Zheshang Industrial Group
Zheshang Industrial Group investment in Series A - LYNK Pharmaceuticals
Decheng Capital
Decheng Capital investment in Series A - LYNK Pharmaceuticals
Med-Fine Capital
Med-Fine Capital investment in Series A - LYNK Pharmaceuticals
Kaitai Capital
Kaitai Capital investment in Series A - LYNK Pharmaceuticals
Official Site Inspections
http://www.en.lynkpharma.com
Unable to get host informations!!!
More informations about "LYNK Pharmaceuticals"
LYNK Pharmaceuticals - Crunchbase Company Profile …
Contact Email [email protected] Phone Number +86 0571-8771117 LYNK Pharmaceuticals is a biotech company focusing on the discovery and …See details»
关于我们 - Lynk Pharma
EN. 中. 凌科致力于 ... 商务拓展: Business Development: [email protected]. 地址-1: ADD-1: 291 Fucheng Road, Bldg 5-402, Qiantang, Hangzhou, Zhejiang 310018, China 浙江省杭州市 …See details»
凌科 - lynkpharma.com
凌科药业是一家处于临床阶段的创新药研发公司，致力于发现和开发用于治疗癌症以及免疫和炎症性疾病的新药。See details»
Lynk Pharmaceuticals - Craft
Lynk Pharmaceuticals has 5 employees at their 1 location and $60 m in total funding,. See insights on Lynk Pharmaceuticals including office locations, competitors, revenue, financials, …See details»
Lynk Pharmaceuticals - Products, Competitors, Financials, …
Aug 13, 2018 Headquarters Location. No. 291, Fucheng Road Room 402, Building 5. Hangzhou, Zhejiang , 310018, China (+86) 0571-87711186See details»
Lynk Pharmaceutical - Owler
Lynk Pharmaceutical’s Profile, Revenue and Employees. Lynk Pharmaceutical is a China based clinical-stage company that discovers and develops novel medicines for the treatment of …See details»
36氪首发 | 「凌科药业」获2亿元C1轮融资，加速推进JAK抑制剂临 …
36氪获悉，创新药研发公司 凌科药业（杭州）有限公司（以下简称“凌科药业”）已完成2亿人民币的c1轮融资。 由盛世投资、泰珑投资与联东投资 ...See details»
Lynk Pharmaceuticals Announced First Patient Dosed in Phase I …
HANGZHOU, China, Aug. 12, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative drug development company, announced …See details»
Lynk Pharmaceuticals announced the completion of Series B …
HANGZHOU, China, Aug. 27, 2021 /PRNewswire/ -- Lynk Pharmaceuticals CO., LTD (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative pharmaceutical R&D company, today …See details»
Lynk Pharmaceuticals and Simcere announced Strategic …
HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to …See details»
Lynk Pharmaceuticals Announces IND Approval of LNK01004 for …
HANGZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that …See details»
Lynk Pharmaceuticals Announced Clinical Approval in China of Its …
HANGZHOU, China, June 25, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative drug development company, announced …See details»
产品 - Lynk Pharma
EN. 中. 凌科专注于 ... 商务拓展: Business Development: [email protected]. 地址-1: ADD-1: 291 Fucheng Road, Bldg 5-402, Qiantang, Hangzhou, Zhejiang 310018, China 浙江省杭州市 …See details»
凌科药业宣布其自主研发的1类新药LNK01003正式获得中国临床许 …
Jun 25, 2021 凌科药业宣布lnk01001治疗特应性皮炎的Ⅲ期临床研究完成首例患者给药See details»
凌科药业宣布LNK01001在治疗强直性关节炎的 Ⅱ 期临床试验中取 …
Aug 23, 2023 在更高目标的驱动下，凌科药业旨在成为市场领导者，通过开发创新疗法，满足未被满足的临床需求。至今为止，凌科药业自主研发的多款I类新药已经进入临床，并在全球展 …See details»
国内在研PROTAC管线（一）：开拓药业、凌科药业医药新闻-ByDr…
⌈ByDrug医药新闻摘要⌋ 2024-02-27 08:50，医药速览：近年来小分子领域出现诸多新技术和新方法，比如靶向蛋白降解技术，是药物发现中具有革命性意义的技术策略，其中发展最快的 …See details»
凌科药业宣布其三靶点激酶抑制剂LNK01002临床I期研究完成首例 …
（医药健闻2021年8月12日讯） 创新药研发公司凌科药业（杭州）有限公司宣布其三靶点激酶抑制剂 lnk01002 临床i期研究在中国完成首例患者给药。该研究是一项评价 lnk01002 在原发性骨 …See details»
站内搜索 - Lynk Pharma
媒体垂询: Public Relations: [email protected] 商务拓展: Business Development: [email protected] 地址-1: ADD-1: 291 Fucheng Road, Bldg 5-402, Qiantang, Hangzhou, …See details»
先声药业官网 - Simcere
2023年8月23日，先声药业与凌科药业（杭州）有限公司（以下简称“凌科药业”）合作的选择性 JAK1抑制剂LNK01001，在治疗强直性脊柱炎的II期临床试验取得主要研究积极结果数据（积 …See details»
Guterres prioritises UN reform to ensure taxpayers’ money ... - UN …
Mar 12, 2025 As of 11 March, only 75 of the 193 Member States have paid their assessed contributions in full towards the $3.72 billion 2025 budget for the Organization – approved by …See details»